Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight ...
OTR Therapeutics may still be keeping its own pipeline under wraps, but Zealand Pharma has seen enough promise in the Chinese ...
Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...
The FDA’s oversight of medical device recalls continues to be plagued by staffing challenges—forcing some activities to be ...
Existing IPF treatments, including Boehringer’s recently approved Jascayd, slow disease progress rather than halt or reverse ...
Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned ...
After securing Medicare reimbursement for its pacemaker-like heart failure (HF) implant, Impulse Dynamics has raised more ...
Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain ...
The FDA is raising the bar for approval of CAR T-cell therapies in oncology. | The FDA is raising the bar for approval of CAR ...
Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback